All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
In some non-lymphoid tissues, the unrearranged T cell receptor gamma (TRG@) locus is expressed. The resulting transcript contains a subset of the TRG@ gene segments and is shorter than TRG@ transcripts expressed in lymphoid tissues. This RefSeq record represents the unrearranged TRG@ locus transcript; the complete TRG@ locus is represented by the genomic RefSeq NG_001336. The transcript represented by this RefSeq has two open reading frames (ORFs) that encode different proteins. The downstream ORF is in the same frame as TRG@ and its protein product is similar to TRG@ proteins. The upstream ORF uses a different reading frame and encodes a novel protein.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C242Z | Human anti-TARP T cell receptor, pCDTCR1 | Human | Human | FPPSPLFFFL | HLA-A2 | Lentiviral | ||
TCR-LA-ZP104 | Anti-TARP (FLRNFSLML) TCR-Like Antibody (Fab-D2), HLA-A*0201-Restricted | Human | Fab-D2 | FLRNFSLML | HLA-A*0201 | |||
TCR-LA-ZP158 | Anti-TARP (FLRNFSLML) TCR-Like Antibody (D2), HLA-A*0201-Restricted | Human | D2 | FLRNFSLML | HLA-A*0201 |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION